{"nctId":"NCT04362761","briefTitle":"A Study Evaluating the Long-Term Safety of Elexacaftor Combination Therapy","startDateStruct":{"date":"2020-05-04","type":"ACTUAL"},"conditions":["Cystic Fibrosis"],"count":172,"armGroups":[{"label":"ELX/TEZ/IVA","type":"EXPERIMENTAL","interventionNames":["Drug: ELX/TEZ/IVA","Drug: IVA"]}],"interventions":[{"name":"ELX/TEZ/IVA","otherNames":["VX-445/VX-661/VX-770","elexacaftor/tezacaftor/ivacaftor"]},{"name":"IVA","otherNames":["VX-770","ivacaftor"]}],"eligibilityModule":{"eligibilityCriteria":"Key Inclusion Criteria:\n\n* Completed study drug treatment in parent study (VX18-445-109); or had study drug interruption(s) in parent study but completed study visits up to the last scheduled visit of the Treatment Period in the parent study\n\nKey Exclusion Criteria:\n\n* History of study drug intolerance in parent study\n\nOther protocol defined Inclusion/Exclusion criteria may apply.","healthyVolunteers":false,"sex":"ALL","minimumAge":"12 Years","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Part A: Safety and Tolerability as Assessed by Number of Participants With Treatment- Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"160","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"26","spread":null}]}]}]},{"type":"PRIMARY","title":"Part B: Safety and Tolerability as Assessed by Number of Participants With Treatment- Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"50","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":26,"n":172},"commonTop":["Headache","Nasopharyngitis","Infective pulmonary exacerbation of cystic fibrosis","Cough","Vaccination complication"]}}}